Huifeng Bio-Pharmaceutical Announces Five-Year Supply Agreement

Chinese drugmaker Huifeng Bio-Pharmaceutical Technology has entered a five-year supply agreement with Sichuan Huafamei Enterprise, a division of France’s Safic Alcan Group.

The agreement grants Safic Alcan exclusive rights to market Diosmin, a semisynthetic phlebotropic drug, in the European market, Huifeng said.

Diosmin is used in the treatment of acute or chronic hemorrhoids in place of rubber-band ligation, in combination with a fiber supplement or as an adjuvant therapy to hemorrhoidectomy to reduce secondary bleeding.